Compare CSBR & BNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CSBR | BNR |
|---|---|---|
| Founded | 1985 | 2014 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 81.0M | 76.5M |
| IPO Year | 2015 | 2019 |
| Metric | CSBR | BNR |
|---|---|---|
| Price | $5.89 | $9.38 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 4.4K | ★ 20.8K |
| Earning Date | 03-12-2026 | 06-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 161.11 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,900,000.00 | N/A |
| Revenue This Year | $4.84 | $111.65 |
| Revenue Next Year | $11.51 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.50 | $3.51 |
| 52 Week High | $9.63 | $41.72 |
| Indicator | CSBR | BNR |
|---|---|---|
| Relative Strength Index (RSI) | 45.13 | 47.38 |
| Support Level | N/A | $8.05 |
| Resistance Level | $6.31 | $9.90 |
| Average True Range (ATR) | 0.43 | 0.82 |
| MACD | -0.06 | 0.50 |
| Stochastic Oscillator | 10.49 | 75.84 |
Champions Oncology Inc is a USA based company which is engaged in the development and sale of state of the art technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment namely Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). Its POS business assists physicians in developing personalized treatment options for their cancer patients through tumor-specific data obtained from drug panels and related personalized oncology services. The TOS business assists pharmaceutical and biotechnology companies with their drug development process and offers studies or license tumors for use in studies. The company's revenue is majorly derived from research services.
Burning Rock Biotech Ltd is a cancer diagnostics company. The Group provides pharma research and development services, mainly cancer therapy selection tests services, companion diagnostics development services, and other service agreements with the combination of various customized tests services and analytical validation services, to pharmaceutical companies for developing new drugs for targeted therapies, immunotherapies on various types of cancers, and to hospitals for their studies on cancer diagnosis & treatment. It had three operating segments, including the Central laboratory business, the In-hospital business, & Pharma research & development services. It generates the majority of its revenue from the Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, & others.